Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan ?: A monocentric institution safety analysis of 46 patients-Reference-Cited by-同舟云学术

Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan ?: A monocentric institution safety analysis of 46 patients

Published:2011-02 Issue:2 Volume:35 Page:125-131
ISSN:2210-7401
Container-title:Clinics and Research in Hepatology and Gastroenterology
language:en
Short-container-title:Clinics and Research in Hepatology and Gastroenterology

Author:

Mineur L.,Sabatier R.,Kirscher S.,Plat F.,Goubely Y.,Molinari N.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference17 articles.

1. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J clin Oncol 2004;22(2):229–37.

2. Colucci G, Gebbia V, Paoletti G et al. Phase III randomised trial of FOLFIRI versus FOLFOX4 in treatment of Advanced Colorectal Cancer: A multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale. J clin Oncol 23:4866–75.

3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000.

4. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

5. E. Van Cutsem, M. Nowacki, I. Lang, S. Cascinu, I. Shchepotin, J. Maurel, P et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the firstline treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial Journal of Clinical Oncology, Annual Meeting Proceedings. Vol 25, No 18S (June 20 Supplement), 2007:4000.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eosinophil plays a crucial role in intestinal mucositis induced by antineoplastic chemotherapy;Immunology;2022-01-10

2. Self-assembled polypeptide nanoparticles for intracellular irinotecan delivery;European Journal of Pharmaceutical Sciences;2017-11

3. The reduction of oxidative stress by nanocomposite Fullerol decreases mucositis severity and reverts leukopenia induced by Irinotecan;Pharmacological Research;2016-05

4. Inflammasome Activation Is Reactive Oxygen Species Dependent and Mediates Irinotecan-Induced Mucositis through IL-1β and IL-18 in Mice;The American Journal of Pathology;2014-07

5. Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis;Current Drug Targets;2013-05-01